Sign In
Buy ARDX
$6.18
-0.190 (-2.98%)
At Close: Jun 23, 2026
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
08:01am, Tuesday, 06'th May 2025
Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress Analysis of IBS in America 2024 Real-World Survey Demonstrates tha
Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty
10:07am, Friday, 02'nd May 2025
Ardelyx's Q1 earnings reveal a sequential drop in revenue and a sharp rise in SG&A expenses, leading to a substantial operational loss. The company faces reimbursement challenges for XPHOZAH, raising
Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript
10:06pm, Thursday, 01'st May 2025
Ardelyx, Inc. (NASDAQ:ARDX ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications and Investor Relations Mike Raab -
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics
07:06pm, Thursday, 01'st May 2025
Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street
Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates
06:40pm, Thursday, 01'st May 2025
Ardelyx (ARDX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.11 per share a year ago.
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
04:01pm, Thursday, 01'st May 2025
Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million Compan
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
08:00am, Tuesday, 29'th Apr 2025
WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class me
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
08:01am, Thursday, 24'th Apr 2025
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class me
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
08:00am, Thursday, 17'th Apr 2025
WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class me
WALTHAM, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class me
WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class me
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
08:02am, Thursday, 13'th Mar 2025
Award established to recognize leaders in the field of chronic kidney disease advocacy Award established to recognize leaders in the field of chronic kidney disease advocacy
Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express +
08:30am, Saturday, 01'st Mar 2025
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, providing investment ideas and sparking discussions on their potential. Edtech company Udemy is seen as on the rise and is a Strong
Tenapanor Approved in China for Hyperphosphatemia
07:00am, Wednesday, 26'th Feb 2025
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval
Ardelyx to Participate in Upcoming Investor Conferences
04:15pm, Tuesday, 25'th Feb 2025
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
